Open house Arzneimittelrabattverträge Carbamazepin, ATC N03AF01
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Carbamazepin, ATC N03AF01
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume commitment. The open-house model means there is no guaranteed spend; actual sales depend o...
The open-house agreement automatically becomes void if a nationwide or land-specific discount contract for the same sub...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jan 2027
- Pharmaceutical discount agreements for Carbamazepine (ATC N03AF01) with AOK Bayern
- Non-exclusive open-house model, not a competitive procurement
Show full summary
This is an open-house model (non-exclusive) for pharmaceutical discount agreements on Carbamazepine (ATC N03AF01) with AOK Bayern, Germany. Any interested pharmaceutical company that meets eligibility can join at any time until December 5, 2026. Contracts run from February 1, 2025 to January 31, 2027. No estimated value is provided. Submission can be in paper or electronic with qualified electronic signature. Only German language allowed.
Risks
No estimated value or volume commitment. The open-house model means there is no guaranteed spend; actual sales depend o...
The open-house agreement automatically becomes void if a nationwide or land-specific discount contract for the same sub...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Only pharmaceutical companies (pharmazeutische Unternehmen) as potential partners
Administrative
- Signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) required
- Submission either in paper (hand-signed, 2 copies) or electronically with qualified electronic signature
Requirements may be incomplete.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Carbamazepin, ATC N03AF01
Open house for non-exclusive discount agreements on Carbamazepine (ATC N03AF01). All eligible pharmaceutical companies can participate. No selection; all accepted.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 15 Dec 2024
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 766649-2024
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume commitment. The open-house model means there is no guaranteed spend; actual sales depend o...
The open-house agreement automatically becomes void if a nationwide or land-specific discount contract for the same sub...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications